Therapeutic Asset Ratings

91,564 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Degarelix Prostate Cancer	Bayer	P4	BBB (72)
Degarelix Prostate Neoplasm	Novartis Pharmaceuticals	P4	BBB (72)
Desvenlafaxine Major Depressive Disorder	Pfizer	P4	BBB (72)
Dexasone Osteoarthritis, Hip	Poznan University of Medical Sciences	P4	BBB (72)
Donanemab Alzheimer Disease	Michael Rafii, MD, PhD	P4	BBB (72)
Duloxetine Depressive Disorder	Huazhong University of Science and Technology	P4	BBB (72)
Duloxetine Osteoarthritis	The Catholic University of Korea	P4	BBB (72)
Efanesoctocog Alfa Hemophilia A	Sanofi	P4	BBB (72)
Elamipretide Trihydrochloride Barth Syndrome	Stealth BioTherapeutics Inc.	P4	BBB (72)
Empagliflozin Type 2 Diabetes Mellitus	Post Graduate Institute of Medical Education and Research, Chandigarh	P4	BBB (72)
Escitalopram Bipolar Depression	Dr. Inge Winter	P4	BBB (72)
Escitalopram Major Depressive Disorder	Shanghai 7th People's Hospital	P4	BBB (72)
Etoposide Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P4	BBB (72)
Etoposide Lymphoblastic Lymphoma	University of Washington	P4	BBB (72)
Etoposide Small Cell Lung Carcinoma	Sichuan University	P4	BBB (72)
Everolimus Pancreatic Neuroendocrine Tumor	Exelixis	P4	BBB (72)
Exemestane Breast Carcinoma In Situ	Alliance for Clinical Trials in Oncology	P4	BBB (72)
Exemestane Invasive Breast Carcinoma	University of California, San Francisco	P4	BBB (72)
Exemestane Breast Carcinoma	Dartmouth-Hitchcock Medical Center	P4	BBB (72)
Factor Ix Hemophilia A	Tulane University	P4	BBB (72)
Factor Viii Inhibitor Bypassing Fraction Hemophilia A	Emory University	P4	BBB (72)
Fampridine Multiple Sclerosis	MGH Institute of Health Professions	P4	BBB (72)
Febuxostat Gout	Haiphong University of Medicine and Pharmacy	P4	BBB (72)
Flortaucipir Primary Progressive Aphasia	Mayo Clinic	P4	BBB (72)
Fluorouracilum Hepatocellular Carcinoma	Li Qiang	P4	BBB (72)

Showing 776 to 800 of 42,327 assets

PreviousPage 32 of 1694Next